Depression Trial Wins, Losses; Americans’ Chronic Insomnia; Kids’ Sleep Anxiety

Another phase III trial of lumateperone as adjunctive therapy in patients with major depressive disorder met its endpoints, significantly reducing Montgomery-Åsberg Depression Rating Scale (MADRS) scores by week 6, said Intra-Cellular Therapies.

In other news, investigational esmethadone — one of the two components of methadone — flopped in a late-stage trial as adjunctive treatment in patients with major depressive disorder with inadequate response to standard antidepressants. (Journal of Clinical Psychiatry)

An American Academy of Sleep Medicine survey found 12% of Americans have been diagnosed with chronic insomnia.

CDC survey data from 2022 showed that 4% of Americans ages 65 and older had ever received a dementia diagnosis. (National Health Statistics Reports)

In partnership with several groups including the American Psychiatric Association, the American Society of Addiction Medicine opened up the draft of its clinical practice guideline on benzodiazepine tapering for public comment until July 19.

Early discontinuation of in-hospital use of long-acting injectables was linked with increased rates of readmission for patients with first-admission schizophrenia in Taiwan. (JAMA Network Open)

Disney’s Inside Out 2 is teaching kids about anxiety. (New York Times)

One in four parents said their young child can’t go to sleep because of being worried or anxious, according to a C.S. Mott Children’s Hospital national poll.

Traumatic brain injury was associated with higher risk of both schizophrenia and bipolar disorder in Sweden, a link not explained by familial confounding. (Psychiatry Research)

Some men may not be able to self-identify an eating disorder. (The Guardian)

Please enable JavaScript to view the

comments powered by Disqus.